跳至主要内容
临床试验/NCT03450031
NCT03450031已完成不适用

Evaluation of Nasal Inflammatory Biomarkers During the Early and Late Phase Response to Nasal Volus Allergen Challenge in in Subjects With Seasonal Allergic Rhinitis (Out-of-season)

Fraunhofer-Institute of Toxicology and Experimental Medicine2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2018年2月8日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
24
试验地点
2
主要终点
Interleukin-4

研究概览

简要总结

This research aims to establish a panel of inflammatory biomarkers of the early (Histamine, Tryptase, ProstaglandineD2) and late (Interleukin-4, Interleukin-5, Interleukin-6, Interleukin-13, Eotaxin, Tumor necrosis factor-a (TNF), (Macrophage Inflammatory Protein-1beta (MIP1ß)) phase response to nasal bolus allergen challenge (NAC) in subjects with out-of-season seasonal allergic rhinitis, suitable for future application in drug intervention studies of novel anti-allergy therapeutics.

详细描述

Biomarkers will be sampled by nasal filter paper (NFP) adsorption and lavage (NLF) prior to and following NAC. Samples from initial subjects (Cohort A; n~6) will be used primarily for validation of biomarker assays in nasal filter paper eluates. Validated biomarker assays will be applied to analyze biomarker changes in a further cohort of subjects (Cohort B; n~12) with the aim of fully defining the optimum panel and sampling time points for future studies.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Able and willing to give written informed consent.
  • Male or female, age 18-65 years.
  • Women will be considered for inclusion if they are:
  • Not pregnant, as confirmed by pregnancy test, and not nursing.
  • Of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchal, or post-menopausal with documented proof of hysterectomy or tubal ligation, or meets clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the screening visit).
  • Of childbearing potential and using a highly effective method of contraception during the entire study, as defined by at least one of the following
  • vasectomised partner
  • sexual abstinence (the lifestyle of the female should be such that there is complete abstinence from intercourse from two weeks prior to Visit 2 procedures until at least 72 hours after NAC)
  • implants, injectables, combined oral contraceptives, hormonal IUDs or double-barrier methods (i.e. any double combination of IUD, condom with spermicidal gel, diaphragm, sponge, and cervical cap)
  • History of seasonal allergic rhinitis to grass pollen with symptoms during the 2016 and 2017 allergen season requiring treatment with anti-histamines, nasal corticosteroids or leukotriene antagonists.
  • Absence of significant current symptoms of allergic rhinitis consistent with being out of season for their principal allergen (eg grass).
  • Skin prick test positive for mixed grass pollen allergen at Visit 1 or within one year prior to screening.

排除标准

  • Asthma requiring more than inhaled short-acting beta-2 agonists.
  • Spirometry showing FEV1 <80% predicted
  • Subjects who have smoked more than 5 cigarettes in the last 6 months or have a smoking history of ≥10 pack years.
  • Upper or lower respiratory tract infection in the prior 4 weeks.
  • Nasal or lung provocation procedure (eg, allergen challenge) conducted in the prior 4 weeks.
  • Significant nasal deformity, recent nasal surgery or obstructing nasal polyps.
  • History of anaphylaxis (any cause), or previous severe hypersensitivity reaction to any of the test agents for SPT or NAC.
  • Recent participation in a study of an investigational medicinal product (IMP) which could interfere with markers evaluated in this research
  • Use of any medications according to section 5.2 in the period indicated before Visit 1

研究组 & 干预措施

NAC (no drug/no device) and NFP

Experimental

NAC with mixed grass pollen will be conducted. Nasal mucosal inflammatory mediators will be collected via nasal filter paper (NFP)

干预措施: NAC (no drug/no device) (Other)

NAC (no drug/no device) and NFP AND NLF

Experimental

NAC with mixed grass pollen will be conducted. Nasal filter paper (NFP)sampling will be conducted from one nostril per time point. Subjects in Cohort B will also undergo nasal lavage (NLF) pre-NAC and at serial time points thereafter up to 8 hours

干预措施: NAC (no drug/no device) (Other)

结局指标

主要结局

Interleukin-4

时间窗: Change from baseline at time points: 1 minutes (min), 4 min, 7 min, 10 min, 15 min, 30 min, 60 min, 120 min, 240 min, 360 min, 480 min

Interlukin- 4 \[pg/ml\] using ELISA assays

次要结局

未报告次要终点

研究者

发起方
Fraunhofer-Institute of Toxicology and Experimental Medicine
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验